Table 4.

Comparison of grade 3 and 4 events in patients treated with capecitabine in trials as opposed 5-FU per a recent meta-analysis of mCRC trials⁴³

G 3/4 AE	No. of trials	No. of patients	OR	95% CI
Thrombocytopenia	6	2612	1.45	0.82–2.55
Diarrhea*	10	4720	1.35	1.16–1.57
Nausea/vomiting	8	4668	1.06	0.84–1.33
Neuropathy	7	4525	1.04	0.82–1.32
Neutropenia*	9	4786	0.15	0.12–0.18

Note:

^*Statistically significant.

Abbreviations: 5-FU, 5-fluorouracil; mCRC, metastatic colorectal cancer; AE, adverse events; OR, odds ratio; CI, confidence interval.